NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.14
+3.24%Next report
Analyst consensus
- Next report date
- Oct 8, 2026
- EPS estimate
- -$0.56
- Revenue estimate
- $23.6M
Latest reported
- Last report date
- Jul 9, 2026
- EPS actual
- -$0.81
- EPS estimate
- -$0.73
- Revenue actual
- $9.0M
- Revenue estimate
- $15.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -8.8%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $35
- PT range
- $25 – $45
- Analysts
- 12
12 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 8, 2026